Vertex Pharmaceuticals Shares Issued for Share-Based Compensation remained flat by 0.0% to $31.93M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 11.4%, from $28.65M to $31.93M. Over 2 years (FY 2023 to FY 2025), Shares Issued for Share-Based Compensation shows relatively stable performance with a -2.6% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Higher issuance increases dilution, which may be a concern if not balanced by strong performance or share buybacks.
This metric represents the number of shares issued to employees or directors as part of equity-based incentive plans. It...
Common metric for analyzing equity dilution and compensation structure.
is_cvx_shares_issued_for_share_based_compensation| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $134.60M | $114.60M | $127.70M |
| YoY Change | — | -14.9% | +11.4% |
We use cookies for analytics. See our Privacy and Cookie Policy.